Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Transtema in conjunction with a rights issue
Mandate

Vinge has advised Transtema in conjunction with a rights issue

October 09, 2018 Capital Markets and Public M&A

Vinge has advised Transtema in connection with a rights issue.

The issue proceeds of approximately MSEK 78 will be used for a part financing in the acquisition of Ericsson Local Services as well as to facilitate future growth efforts.

The prospectus was approved by the Swedish Financial Supervisory Authority on 14 September 2018 and the subscription period expired on 1 October 2018.

Vinge’s team primarily consisted of Anders Strid, Wibeke Sorling, Natalie Bäck and corporate assistant Camilla Andersson.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026